liver cancer
Conditions
Interventions
Group A:Epirubicin hydrochloride 40mg, iodine 5ml
Group B:Genmzar 1000mg, iodine 5ml
Group C:hydroxycamptothecia 10mg, iodine 5ml
Group D:Epirubicin hydrochloride 40mg+Genmzar 1000mg, iodine 5ml
Group E:Epirubicin hydrochloride 40mg+hydroxycamptothecia 10mg, iodine 5ml
Group F:Genmzar 1000mg+hydroxycamptothecia 10mg, iodine 5ml
Sponsors
Eastern Hepatobiliary Surgery Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. postoperative liver cancer who need prevent the recurrent; 2. both male and female; 3. diagnosed 'liver cancer'; 4. without any recurrent in liver in CT or MRI; 5. Liver function (Child grade) grading higher than B (include B); 6. not received other chemotherapy or obstruct therapy.
Exclusion criteria
Exclusion criteria: Irritability for iodine; Combined with other tumours; Complicated with unstable angina, congestive heart-failure (heart function grade VI) and uncontrolled hypertension, arrhythmia, sever infection, uncontrolled and unstable diabetes.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| number and size of tumor;stable and progress of illness; | — |
Secondary
| Measure | Time frame |
|---|---|
| AFP, CA19-9; | — |
Countries
China
Contacts
Public ContactHongyan Chen
Outcome results
None listed